Drug intelligence / Profile preview

SRT-002

Development stage: Preclinical
Lead developer: San Rocco Therapeutics
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies

Overview

SRT-002 is a gene therapy drug candidate developed by San Rocco Therapeutics. It is being investigated for the treatment of neoplasms (cancers). As of March 2025, its highest global research and development status is preclinical, meaning it has not yet entered human clinical trials. The specific mechanism of action and molecular targets for SRT-002 have not been publicly disclosed. The drug represents part of San Rocco Therapeutics' pipeline focused on innovative therapies for serious diseases such as cancer[1][9].

Other names: SRT-002SRT002SRT 002

Beyond the preview

Go deeper on SRT-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRT-002.

Explore the full profile